Ignite Creation Date:
2024-05-06 @ 1:02 PM
Last Modification Date:
2024-10-26 @ 1:08 PM
Study NCT ID:
NCT03919994
Status:
COMPLETED
Last Update Posted:
2023-02-02
First Post:
2019-04-01
Brief Title:
Observational Study of Long Acting Injectable Medications LAIs in Schizophrenia OASIS
Sponsor:
Alkermes Inc
Organization:
Alkermes Inc
Study Overview
Official Title:
OASIS Observational Study of LAIs In Schizophrenia
Status:
COMPLETED
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objectives of this study are to describe characteristics treatment patterns and outcomes of patients with schizophrenia newly initiated on 1 of 4 FDA-approved atypical Long Acting Injectable LAI antipsychotics ABILIFY MAINTENA ARISTADA INVEGA SUSTENNA or RISPERDAL CONSTA
Detailed Description:
This is a non-interventional prospective multi-center observational cohort study Patients at behavioral health clinics will be enrolled and evaluated by health care professionals eg psychiatrists according to the standard of care All patients will be followed for approximately 12 months from their enrollment visit
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None